Cullinan Oncology is a biopharmaceutical company. Zipalertinib (CLN-081/TAS6417) which Co. is co-developing with an affiliate of Taiho Pharmaceutical, Co. Ltd (Taiho), is an orally bioavailable small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 insertion (EGFRex20ins) mutations with relative sparing of cells expressing wild-type EGFR. In addition to zipalertinib, Co.'s portfolio includes four other clinical-stage product candidates and one product candidate that is pending the U.S. Food and Drug Administration clearance for its investigational new drug application. We show 14 historical shares outstanding datapoints in our CGEM shares outstanding history coverage, used to compute CGEM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CGEM market cap history over the course of time is important for investors
interested in comparing CGEM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CGEM versus a peer is one thing; comparing
CGEM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CGEM can fluctuate over the course of history.
With this page we aim to empower investors researching CGEM by allowing them to research the CGEM market cap history. |
Free CGEM Email Alerts:
Video: The Importance of Market Cap
